| Literature DB >> 24476707 |
Gunther Antonissen1, An Martel2, Frank Pasmans3, Richard Ducatelle4, Elin Verbrugghe5, Virginie Vandenbroucke6, Shaoji Li7, Freddy Haesebrouck8, Filip Van Immerseel9, Siska Croubels10.
Abstract
Contamination of food and feed with mycotoxins is a worldwide problem. At present, acute mycotoxicosis caused by high doses is rare in humans and animals. Ingestion of low to moderate amounts of Fusarium mycotoxins is common and generally does not result in obvious intoxication. However, these low amounts may impair intestinal health, immune function and/or pathogen fitness, resulting in altered host pathogen interactions and thus a different outcome of infection. This review summarizes the current state of knowledge about the impact of Fusarium mycotoxin exposure on human and animal host susceptibility to infectious diseases. On the one hand, exposure to deoxynivalenol and other Fusarium mycotoxins generally exacerbates infections with parasites, bacteria and viruses across a wide range of animal host species. Well-known examples include coccidiosis in poultry, salmonellosis in pigs and mice, colibacillosis in pigs, necrotic enteritis in poultry, enteric septicemia of catfish, swine respiratory disease, aspergillosis in poultry and rabbits, reovirus infection in mice and Porcine Reproductive and Respiratory Syndrome Virus infection in pigs. However, on the other hand, T-2 toxin has been shown to markedly decrease the colonization capacity of Salmonella in the pig intestine. Although the impact of the exposure of humans to Fusarium toxins on infectious diseases is less well known, extrapolation from animal models suggests possible exacerbation of, for instance, colibacillosis and salmonellosis in humans, as well.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24476707 PMCID: PMC3942744 DOI: 10.3390/toxins6020430
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
European Union limits for foodstuffs for human consumption, feed material and finished feed for animals adapted from the European Commission Regulation No 1881/2006 [109] and the European Commission Recommendations 2006/576/EC [110] and 2013/165/EU [111]
| Mycotoxin | Foodstuffs for human consumption/finished animal feed | Maximum levels (µg/kg) |
|---|---|---|
| unprocessed cereals other than durum wheat, oats and maize | 1250 | |
| unprocessed durum wheat and oats | 1750 | |
| unprocessed maize, with the exception of unprocessed maize intended to be processed by wet milling | 1750 | |
| cereals intended for direct human consumption, cereal flour, bran and germ as end product marketed for direct human consumption, with the exception of foodstuffs listed in (1). | 750 | |
| pasta (dry) | 750 | |
| bread (including small bakery wares), pastries, biscuits, cereal snacks and breakfast cereals | 500 | |
| (1) processed cereal-based foods and baby foods for infants and young children | 200 | |
| cereals and cereal products with the exception of maize by-products | 8000 | |
| maize by-products | 12,000 | |
| all animal species with the exception of (2) | 5000 | |
| (2) complementary and complete feedingstuffs for pigs | 900 | |
| (2) complementary and complete feedingstuffs for calves (<4 months), lambs and kids | 2000 | |
| unprocessed cereals other than maize | 100 | |
| unprocessed maize with the exception of unprocessed maize intended to be processed by wet milling | 350 | |
| cereals intended for direct human consumption, cereal flour, bran and germ as end product marketed for direct human consumption, with the exception of foodstuffs listed in (2) | 75 | |
| refined maize oil | 400 | |
| bread (including small bakery wares), pastries, biscuits, cereal snacks and breakfast cereals, excluding maize snacks and maize-based breakfast cereals | 50 | |
| (2) maize intended for direct human consumption, maize-based snacks and maize-bases breakfast cereals | 100 | |
| (2) processed cereal-based foods (excluding processed maize-based foods) and baby foods for infants and young children | 20 | |
| (2) processed maize-based foods for infants and young children | 20 | |
| cereals and cereal products with the exception of maize by-products | 2000 | |
| maize by-products | 3000 | |
| complementary and complete feedingstuffs for piglets and gilts (young sows) | 100 | |
| complementary and complete feedingstuffs for sows and fattening pigs complementary and complete feedingstuffs for calves, dairy cattle, sheep (including lamb) and goats (including kids) | 250 | |
| complementary and complete feedingstuffs for calves, dairy cattle, sheep (including lamb) and goats (including kids) | 500 | |
| unprocessed maize with the exception of unprocessed maize intended to be processed by wet milling | 4000 | |
| maize intended for direct human consumption, maize-based foods for direct human consumption, with the exception of foodstuffs listed in (3) | 1000 | |
| (3) maize-based breakfast cereals and maize-based snacks | 800 | |
| (3) processed maize-based foods and baby foods for infants and young children | 200 | |
| maize and maize products | 60,000 | |
| complementary and complete feedingstuffs for pigs, horses (
| 5000 | |
| complementary and complete feedingstuffs for fish | 10,000 | |
| complementary and complete feedingstuffs for poultry, calves (<4 months), lambs and kids | 20,000 | |
| complementary and complete feedingstuffs for adult ruminants (>4 months) and mink | 50,000 | |
| barley (including malting barley) and maize | 200 | |
| oats (with husk) | 1000 | |
| wheat, rye and other cereals | 100 | |
| oats | 200 | |
| maize | 100 | |
| other cereals | 50 | |
| oat bran and flaked oats | 200 | |
| cereal bran except oat bran, oat milling products other than oat bran and flaked oats, and maize milling products | 100 | |
| other cereal milling products | 50 | |
| breakfast cereals including formed cereal flakes | 75 | |
| bread (including small bakery wares), pastries, biscuits, cereal snacks, pasta | 25 | |
| cereal-based foods for infants and young children | 15 | |
| oat milling products (husks) | 2000 | |
| other cereal products | 500 | |
| compound feed, with the exception of feed for cats | 250 |
(DON = deoxynivalenol, ZEN= zearalenone, T-2= T-2 toxin, HT-2= HT-2 toxin, FB1 = fumonisin B1, FB2 = fumonisin B2)
Figure 1The effect of Fusarium mycotoxins on the intestinal epithelium. A variety of Fusarium mycotoxins alter the different intestinal defense mechanisms including epithelial integrity, cell proliferation, mucus layer, immunoglobulins (Ig) and cytokine production. (IEC: intestinal epithelial cell) (based on [9]).
The influence of Fusarium mycotoxins on infectious diseases in animals: in vivo approach.
| Mycotoxin | Exposure dose | Exposure period | Animal species | Age | Pathogen | Effect: compared to negative control | Reference(s) |
|---|---|---|---|---|---|---|---|
| DON, 15-acetylDON, ZEN and fumonisins | 6.5 mg DON, 0.44 mg 15-acetylDON, 0.59 mg ZEN and 0.37 mg fumonisins/kg feed | 6 weeks | chicken (broiler) | 1 day | ↓ percentage of CD4+ and CD8+ T cells in jejunal mucosa | [ | |
| DON, 15-acetylDON and ZEN | 3.8 mg DON and 0.3 mg 15-acetylDON and 0.2 mg ZEN/kg feed | 10 weeks | chicken (broiler) | 1 day | ↓ level of blood monocytes at end of challenge period; percentage of CD8+ T-cells not. Restored at end of recovery period; ↑ IFN-γ gene expression | [ | |
| DON, 15-acetylDON and ZEN | 3.8 mg DON, 0.3 mg 15-acetylDON and 0.2 mg ZEN/kg feed | 10 weeks | chicken (broiler) | 1 day | ↓ intestinal recovery: duodenal villus height and apparent villus surface area | [ | |
| DON | 1 µg/mL | 6 h | pig | 5 weeks | synergistic ↑ gene expression IL-12, TNF-α, IL-1β, IL-8, MCP-1 and IL-6 | [ | |
| T-2 | 15 and 83 µg/kg feed | 23 days | pig | 3 weeks | ↓ colonization of the cecum | [ | |
| FB1 and FB2 | 8.6 mg FB1 and 3.2 mg FB2/kg feed | 9 weeks | pig | 4 weeks | synergistic transient effect digestive microbiota balance | [ | |
| T-2 | 2 mg/kg BW | 2 days | chicken (broiler) | 1 day | ↑ mortality | [ | |
| T-2 | 1 mg/kg BW | 3 weeks | mouse | 5–6 weeks | ↑ mortality | [ | |
| T-2 | 1 mg/kg BW | 10 days | mouse | 5–6 weeks | ↑ bacteria-related organ lesions | [ | |
| T-2 | 2 mg/kg BW | s.a. | mouse | - | ↑ mortality | [ | |
| DON | 1 mg/L drinking water | 3 weeks | mouse | 7 weeks | ↑ translocation to mesenteric lymph node, liver and spleen | [ | |
| FB1 | 150 mg/kg feed | 6 weeks | Japanese quail | 1 day | ↑ clinical signs and mortality; | [ | |
| FB1 | 0.5 mg/kg BW | 6 days | pig | 3 weeks | ↑ intestinal colonization; | [ | |
| FB1 | 1 mg/kg BW | 10 days | pig | 3–4 weeks | intestinal infection prolonged; impaired function of intestinal antigen presenting cells | [ | |
| fumonisins and aflatoxin | a 50–350 ng fumonisins /mL and 1–3 ng aflatoxin/mL | – | calf | <1 month | ↑ susceptibility to hemorrhagic enteritis | [ | |
| moniliformin | 75–100 mg/kg feed | 3 weeks | chicken (broiler) | 0 day | ↓ bacterial clearance | [ | |
| moniliformin and FB1 | 100 mg moniliformin and 200 mg FB1/kg feed | 3 weeks | turkey | 0 day | ↓ bacterial clearance | [ | |
| DON | 4–5 mg/kg feed | 3 weeks | chicken (broiler) | 1 day | ↑ number of chickens with necrotic enteritis | [ | |
| DON | 5–10 mg/kg feed | 10 weeks | channel catfish | juvenile | ↓ mortality | [ | |
| T-2 | 1–2 mg/kg | 6 weeks | channel catfish | juvenile | ↑ mortality | [ | |
| FB1, FB2 and FB3 | 20 mg FB1, 3.5 mg FB2 and 1.9 mg FB3/kg feed | 42 days | pig | 3 days | ↑ severity of the pathological changes | [ | |
| FB1 | 10 mg/kg feed | 24 days | pig | 3 days | ↑ extent and severity of the pathological changes | [ | |
| FB1 | 0.5 mg/kg BW | 7 days | pig | piglets | ↓ growth rate and ↑ coughing; ↑ total number of cells, number of macrophages and lymphocytes in BALF; ↑ gross pathological lesions and histopathological lesion of lungs | [ | |
| T-2 | mg/mouse ≈ 3.3 mg/kg BW | 20 days | mouse | adult | ↑ bacterial count in spleen | [ | |
| T-2 | 0.1 mg/mouse ≈ 3.3 mg/kg BW | 20 days | mouse | adult | ↓ mouse survival time | [ | |
| T-2 | 0.5 mg/kg BW | 21 days | rabbit | – | ↓ phagocytosis by alveolar macrophages | [ | |
| T-2 | 2 mg/kg BW | s.a. | mouse | – | ↓ phagocytosis by peritoneal macrophages | [ | |
| DON | 25 mg/kg BW | s.a. | mouse | 7–10 weeks | reovirus (serotype 1) | ↓ viral clearance and ↑ fecal shedding↓ Th1 response by ↓ IFN-γ gene expression↑ intestinal IgA and ↑ Th 2 response: by ↑ IL-4, IL-6 and IL-10 gene expression | [ |
| T-2 | 1.75 mg/kg BW | s.a. | mouse | 7–10 weeks | reovirus (serotype 1) | ↓ viral clearance and ↑ fecal shedding; | [ |
| FB1 | 12 mg/kg BW | 18 days | pig | 1 month | PRRSV15 | ↑ histopathological lesions of lungs | [ |
DON = deoxynivalenol; T-2 = T-2 toxin; ZEN = zearalenone; FB1 = fumonisin B1; FB2 = fumonisin B2; FB3 = fumonisin B3; BW = bodyweight; a mycotoxin level detected in the hemorrhaged mucosa; s.a. = single administration; 1 Eimeria; 2 septicemic Escherichia coli; 3 enterotoxigenic Escherichia coli; 4 shiga toxin producing Escherichia coli; 5 avian pathogenic Escherichia coli; 6 Clostridium perfringens; 7 Edwardsiella ictaluri; 8 Mycoplasma hyopneumoniae; 9 Bordetella bronchiseptica; 10 Pasteurella multocida; 11 Mycobacterium tuberculosis; 12 Mycobacterium bovis; 13 Aspergillus fumigatus; 14 Pseudomonas aeroginosa; 15 PRRSV = Porcine Reproductive and Respiratory Syndrome Virus.
Figure 2The impact of deoxynivalenol and T-2 toxin on a Salmonella Typhimurium infection in pigs. In vitro, deoxynivalenol (DON) and T-2 toxin (T-2) promote Salmonella invasion (1) and transepithelial passage (2) of IPEC-J2 cell layer. Subsequently, the bacterium can spread to the bloodstream using the host macrophage to establish the systemic infection. In vitro, DON and T-2 enhance Salmonella uptake (3) in porcine alveolar macrophages. The Salmonella invasion of macrophages coincides with membrane ruffling, caused by actin cytoskeletal changes. Activation of host Rho GTPases by the Salmonella pathogenicity island (SPI)-1 type 3 secretion system (T3SS) effector proteins SopB, SopE, SopE2 and SopD leads to actin cytoskeleton reorganization. After Salmonella internalization has occurred, the bacterium injects the effector protein SptP which promotes the inactivation of Rho GTPases. The bacterium can also modulate the actin dynamics of the host cell in a direct manner through the bacterial effector proteins SipA and SipC. The mycotoxin DON enhances the uptake of Salmonella in macrophages through activation of the mitogen-activated protein kinases (MAPK) extracellular signal-regulated kinases (ERK1/2) pathway, which induces actin reorganizations and membrane ruffles. DON and T-2 do not affect intracellular bacterial proliferation (4) (based on [41,44]).
Interaction between Fusarium mycotoxins and infectious diseases: in vitro approach.
| Mycotoxin | Exposure dose | Exposure period | Cell line (host species) | Pathogen | Effect | Reference(s) |
|---|---|---|---|---|---|---|
| DON or T-2 | >25 ng DON/mL or 5 ng T-2/mL; | 24 h | undifferentiated IPEC1-J2; | ↑ invasion | [ | |
| DON or T-2 | 0.5 µg DON/mL or ≥1.0 ng T-2/mL | 24 h | differentiated IPEC1-J2 (pig) | ↑ translocation | [ | |
| DON or T-2 | 0.025 µg DON/mL or 1 ng T-2/mL | 24 h | PAM2 (pig) | ↑ invasion | [ | |
| DON | 5–50 µM (1.5–15 µg/mL) | 48 h | IPEC1-J1 (pig) | ↑ translocation | [ | |
| T-2 | 0.001 µM | 6 h | peritoneal macrophages (mouse) | ↓ phagocytosis | [ | |
| T-2 | 0.01−0.05 µM | 20 h | alveolar macrophages (rat) | ↓ phagocytosis | [ | |
| T-2 | 0.1 µM | 6 h | alveolar macrophages (rat) | ↓ phagocytosis | [ | |
| T-2 | 1–5 ng/mL; 2–5 ng/mL | 24 h | HD-11 cell line8 (chicken) | ↓ phagocytosis; | [ |
DON = deoxynivalenol; T-2=T-2 toxin; 1 IPEC = Intestinal Porcine Epithelial Cell; 2 PAM = porcine alveolar macrophage; 3 septicemic Escherichia coli; 4 Pseudomonas aeruginosa; 5 Saccharomyces cerevisae; 6 Staphylococcus aureus; 7 Aspergillus fumigatus; 8 chicken macrophages; (A) = increased gene expression of IL-1β, IL-6, CCLi1, CXCLi1, CXCLi2, IL-18 and IL-12β.